Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2021

View Archived Issues

FDG-PET signal is substantially affected by microglial glucose uptake in neurodegenerative diseases

New spondyloarthritis therapeutic target identified

Elevated plasma CXCL16 levels found in severe COVID-19 patients

LRFN1 gene as a possible cause of autism spectrum disorder

Discovery of broad-spectrum inhibitor of oncogenic BRAF dimerization

Role of de novo mutations in severe male infertility

Hutchison MediPharma patents new CSF1R inhibitors

Chinese researchers disclose new ROS inhibitors

Whole exome sequencing analysis identifies novel genes associated with osteoarthritis

Angiex presents new TM4SF1-targeting PROTACs

Dongguan Hec New Drug Research and Development synthesizes new HBV antivirals

Medshine Discovery describes new compounds for cancer

Alu RNA induces retinal pigment epithelium degeneration in geographic atrophy via the inflammasome

Mitochondrial augmentation: a promising disease-modifying strategy for mitochondrial DNA disorders

NPAS3 identified as a risk gene for autism spectrum disorder

Tango Therapeutics' MTAPnull PRMT5 inhibitor TNG-908 active in multiple xenograft tumor models

HLA fine mapping identifies INPP5A as a risk gene for tuberculosis

Oncodesign and TiumBio collaborate to discover and develop candidates for fibrosis

Mablink and Emergence enter licensing agreement for ADC targeting Nectin-4

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...